Smith, Salley & Associates Abb Vie Inc. Transaction History
Smith, Salley & Associates
- $1.35 Billion
- Q2 2024
A detailed history of Smith, Salley & Associates transactions in Abb Vie Inc. stock. As of the latest transaction made, Smith, Salley & Associates holds 165,249 shares of ABBV stock, worth $32.2 Million. This represents 2.1% of its overall portfolio holdings.
Number of Shares
165,249
Previous 157,004
5.25%
Holding current value
$32.2 Million
Previous $28.6 Million
0.86%
% of portfolio
2.1%
Previous 2.29%
Shares
28 transactions
Others Institutions Holding ABBV
# of Institutions
3,694Shares Held
1.27BCall Options Held
13MPut Options Held
9.79M-
Vanguard Group Inc Valley Forge, PA171MShares$33.2 Billion0.57% of portfolio
-
Black Rock Inc. New York, NY136MShares$26.6 Billion0.54% of portfolio
-
State Street Corp Boston, MA77.8MShares$15.2 Billion0.59% of portfolio
-
Jpmorgan Chase & CO New York, NY53.6MShares$10.4 Billion0.81% of portfolio
-
Capital International Investors Los Angeles, CA38.6MShares$7.52 Billion1.4% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $344B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...